Achondroplasia Clinical Trials
TransCon CNP 100 Mcg
for Achondroplasia
3 - 15
All Sexes
Little Rock, AR
This trial will study the effects of TransCon CNP on people aged 2-18 with achondroplasia. Treatment will continue until femur and tibial epiphyseal closure is confirmed, with visits every 12-14 weeks.
Phase 2 & 3
Waitlist Available
Has No Placebo
Learn More
Ascendis Pharma Investigational Site (+3 Sites)
Silas Gylvin, MD
Ascendis Pharma Growth Disorders A/S
BMN 111 Injection With Injector Pen
for Achondroplasia
18 - 55
All Sexes
Dallas, TX
This trial looks at if a single dose of medicine is the same when injected using two different devices.
Phase 1
Recruiting
Has No Placebo
Learn More
Labcorp
BioMarin Pharmaceutical
TransCon CNP
for Achondroplasia
2 - 11
All Sexes
Montréal, Canada
This trial tests a drug to help with growth in children 2-11 with Achondroplasia. It's a double-blind, placebo-controlled study with an Open Label Extension.
Phase 2 & 3
Waitlist Available
Drug
Learn More
Ascendis Pharma Investigational Site (+4 Sites)
Ascendis Pharma Growth Disorders A/S
View More